D. E. Shaw & Co., Inc. Vir Biotechnology, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 502,000 shares of VIR stock, worth $4.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
502,000
Previous 930,655
46.06%
Holding current value
$4.8 Million
Previous $6.97 Million
47.14%
% of portfolio
0.0%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding VIR
# of Institutions
231Shares Held
90.1MCall Options Held
1.28MPut Options Held
235K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$160 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$157 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$126 Million0.0% of portfolio
-
State Street Corp Boston, MA5.07MShares$48.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.22MShares$30.8 Million0.64% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.27B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...